Ma, L., Pang, Z., Zhang, H., Yang, X., Zheng, S., Chen, Y., Ding, W., Han, Q., Zhang, X., Cao, L., Fei, T., Wang, Q., Gao, D., He, A., Hu, K.-B., Li, X., & Sheng, R. (2025). Clear cell renal carcinoma essentially requires CDKL3 for oncogenesis. Proceedings of the National Academy of Sciences, 122(7). https://doi.org/10.1073/pnas.2415244122

Singla, N., Nirschl, T. R., Obradovic, A. Z., Shenderov, E., Lombardo, K., Liu, X., Pons, A., Zarif, J. C., Rowe, S. P., Trock, B. J., Hammers, H. J., Bivalacqua, T. J., Pierorazio, P. M., Deutsch, J. S., Lotan, T. L., Taube, J. M., Ged, Y. M. A., Gorin, M. A., Allaf, M. E., & Drake, C. G. (2024). Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma. Scientific Reports, 14(1). https://doi.org/10.1038/s41598-024-51889-9

Lin, C.-C., Garralda, E., Schöffski, P., Hong, D. S., Siu, L. L., Martin, M., Maur, M., Hui, R., Soo, R. A., Chiu, J., Zhang, T., Ma, B., Kyi, C., Tan, D. S., Cassier, P. A., Sarantopoulos, J., Weickhardt, A., Carvajal, R. D., Spratlin, J., … De Braud, F. (2023). A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies. OncoImmunology, 13(1). https://doi.org/10.1080/2162402x.2023.2290787

Ager, C. R., Zhang, M., Chaimowitz, M., Bansal, S., Tagore, S., Obradovic, A., Jugler, C., Rogava, M., Melms, J. C., McCann, P., Spina, C., Drake, C. G., Dallos, M. C., & Izar, B. (2023). KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response. Journal for ImmunoTherapy of Cancer, 11(9), e006782. https://doi.org/10.1136/jitc-2023-006782

Goodstein, T., Yang, Y., Runcie, K., Srinivasan, R., & Singer, E. A. (2023). Two is company, is three a crowd? Triplet therapy, novel molecular targets, and updates on the management of advanced renal cell carcinoma. Current Opinion in Oncology, 35(3), 206–217. https://doi.org/10.1097/cco.0000000000000939

Dason, S., Lacuna, K., Hannan, R., Singer, E. A., & Runcie, K. (2023). State of the Art: Multidisciplinary Management of Oligometastatic Renal Cell Carcinoma. American Society of Clinical Oncology Educational Book, 43. https://doi.org/10.1200/edbk_390038

Sanborn, R. E., Pishvaian, M. J., Callahan, M. K., Weise, A., Sikic, B. I., Rahma, O., Cho, D. C., Rizvi, N. A., Sznol, M., Lutzky, J., Bauman, J. E., Bitting, R. L., Starodub, A., Jimeno, A., Reardon, D. A., Kaley, T., Iwamoto, F., Baehring, J. M., Subramaniam, D. S., … Keler, T. (2022). Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. Journal for ImmunoTherapy of Cancer, 10(8), e005147. https://doi.org/10.1136/jitc-2022-005147

He, X., Zhou, S., Dolan, M., Shi, Y., Wang, J., Quinn, B., Jahagirdar, D., Huang, W.-C., Tsuji, M., Pili, R., Ito, F., Ortega, J., Abrams, S. I., Ebos, J. M. L., & Lovell, J. F. (2021). Immunization with short peptide particles reveals a functional CD8+T-cell neoepitope in a murine renal carcinoma model. Journal for ImmunoTherapy of Cancer, 9(12), e003101. https://doi.org/10.1136/jitc-2021-003101